The use of mouse models in biomedical research has been pivotal in understanding human diseases due to their genetic and physiological similarities to humans. However, concerns on ethics and translatability have prompted a shift towards alternative methods such as complex in vitro models (CIVMs). PRIM-TECH3R addresses this shift by leveraging advanced technologies to develop reliable mouse and human CIVMs for preclinical studies, aiming to reduce and refine the use of animal models. Through standardised protocols and robust validation procedures, the project will create state-of-the-art in vitro models from mouse disease models, complementing existing in vivo models. This initiative aligns with EU policy objectives and societal demands to address phasing out of animal testing in biomedical research. The project will establish a comprehensive repository of preclinical resources, ensure open access, and foster collaboration between research infrastructures and the biomedical industry. Training programmes will equip personnel with the necessary skills to provide CIVMs to the research community. By achieving these objectives, PRIM-TECH3R aims to advance the state-of-the-art in research infrastructures, facilitate industrial exploitation, and contribute to transformative changes in biomedical research practices.

In response to the HORIZON-INFRA-2023-DEV-01-03 call, INFRAPLUS aims to expand INFRAFRONTIER's capacity for human disease modelling, refine its service portfolio by reducing animal usage and developing alternative cellular models, and optimise the use of resources. INFRAPLUS seeks to achieve several objectives: Developing national node capacities and expertise for providing innovative in vivo, in vitro and preclinical services, developing novel model systems and services to meet the demands of existing and novel user communities, and reducing environmental impact. To achieve these objectives, INFRAPLUS will focus on launching pilot services, refining new technologies, emphasising alternate cellular models, designing and implementing special training programmes and optimising resources for the entire consortium. The project includes a defined service development strategy supported by a strong IT and data management backbone and is built upon the needs of the scientific community. Ultimately, INFRAPLUS will enhance and evolve INFRAFRONTIER's capacity for modelling human diseases and enable breakthrough research by providing researchers cutting-edge tools and services to respond to global biomedical challenges.